Impact of Empagliflozin on Proteinuria in Patients with Type 2 Diabetes Mellitus

Assessment of empagliflozin impact on proteinuria in type 2 diabetic patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190425043368N2

Enrollment

Registered

2025-10-15

Start date

2025-10-23

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Proteinuria in type 2 diabetes. Type 2 diabetes mellitus with other diabetic kidney complication

Interventions

Intervention 1: Intervention group: They will receive Empagliflozin once daily for a duration of 12 weeks. Intervention 2: Control group: They will receive placebo once daily for a duration of 12 week

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients HbA1c=9% eGFR=30 Microalbumin > 20 Antidiabetic medication doses remained unchanged for a minimum of three months prior to the study

Exclusion criteria

Exclusion criteria: Active urinary tract infection Prior use of Empagliflozin before the study Lack of consent to participate in the study

Design outcomes

Primary

Measure	Time frame
The amount of protein in the urine. Timepoint: 3 months. Method of measurement: Urine analysis.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahtabalsadat Mirjalili

Yazd University of Medical Sciences

Mahtab.mirjalili@gmail.com+98 35 3820 3419

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026